THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY |For Healthcare Professionals

THE TABLET CHOICE IN BOWEL PREPARATION

More than 1 Million Prescriptions
Efficacy
Efficacy
of patients in two pivotal trials achieved successful bowel cleansing with SUTAB2,3*
Tolerability
Tolerability
of patients in one pivotal trial rated SUTAB as tolerable to very easy to consume2†
  • 52% of all SUTAB and MoviPrep® patients reported at least one selected gastrointestinal adverse reaction2,3‡
  • More SUTAB patients reported experiencing nausea and vomiting than competitor, with ≤1% of these reports considered severe2‡
Compliance
Compliance
of patients in two pivotal trials were able to complete both doses of preparation2,3
Patient Acceptance
Patient Acceptance

Nearly 4 out of 5 patients (78%) in one pivotal trial would request SUTAB again for a future colonoscopy2†

Dose Kit

Tablets and packaging not shown actual size.

*Success was the primary endpoint and was defined in non-inferiority trials as an overall cleansing assessment of 3 (good) or 4 (excellent) by the blinded endoscopist; scores were assigned following completion of the colonoscopy.
Patients completed a preference questionnaire following completion of study drug to capture their perceptions of the preparation experience. This questionnaire has not undergone formal validation.
Patients were queried for selected gastrointestinal adverse reactions of upper abdominal pain, abdominal distension, nausea, and vomiting following completion of study drug, rating the intensity as mild, moderate, or severe.2,3
MoviPrep is a registered trademark of Velinor AG.
Activate your savings voucher

Activate your
savings copay card

Start Here
SEE THE LATEST ABOUT SUTAB®
IN THE NEWS
SUTAB
IMPORTANT SAFETY INFORMATION

INDICATION
SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

CONTRAINDICATIONS
Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUTAB.

DOSAGE AND ADMINISTRATION
A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed until after the colonoscopy. Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Water must be consumed with each dose of SUTAB and additional water must be consumed after each dose. Complete all SUTAB tablets and required water at least 2 hours before colonoscopy.

WARNINGS AND PRECAUTIONS
Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. Suspected GI obstruction or perforation: Rule out the diagnosis before administration. Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur.

ADVERSE REACTIONS
Most common gastrointestinal adverse reactions are: nausea, abdominal distension, vomiting, and upper abdominal pain.

DRUG INTERACTIONS
Drugs that increase risk of fluid and electrolyte imbalance.

View the Full Prescribing Information and Medication Guide.

References: 1. IQVIA, National Prescription Audit Report. May 2022. 2.Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi: 10.14309/ajg.0000000000001020. 3. SUTAB® [package Insert]. Braintree, MA: Braintree Laboratories, Inc. 4. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 (corrected). Am J Gastroenterol. 2009;104(3):739-750.